Biomea Fusion | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings
2025.11.04 21:21
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.27, beating the estimate of USD -0.3034.

EBIT: As of FY2025 Q3, the actual value is USD -20.81 M.

Segment Revenue

Biomea Fusion, Inc. has not generated any revenue from product sales since its inception.

Operational Metrics

  • Net Loss: For the three months ended September 30, 2025, the net loss was $16.4 million, compared to $32.8 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $66.4 million, compared to $109.1 million for the same period in 2024.
  • Total Operating Expenses: For the three months ended September 30, 2025, total operating expenses were $20.8 million, compared to $34.0 million for the same period in 2024. For the nine months ended September 30, 2025, total operating expenses were $71.8 million, compared to $114.0 million for the same period in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was $56.4 million, compared to $89.9 million for the same period in 2024.
  • Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $44.8 million, compared to $1.3 million for the same period in 2024.

Unique Metrics

  • Research and Development Expenses: For the three months ended September 30, 2025, research and development expenses were $14.4 million, compared to $27.2 million for the same period in 2024. For the nine months ended September 30, 2025, research and development expenses were $53.9 million, compared to $92.8 million for the same period in 2024.

Future Outlook and Strategy

  • Core Business Focus: Biomea Fusion, Inc. is focusing on the development of icovamenib for type 1 and type 2 diabetes, with ongoing Phase II clinical trials. The company is also advancing BMF-650, a GLP-1 receptor agonist, with a Phase I trial expected to provide data in the first half of 2026.
  • Non-Core Business: The company plans to conclude studies exploring icovamenib’s potential in oncology and explore partnerships to further advance its oncology assets, including BMF-500.
  • Priority: The company aims to utilize its FUSION™ System platform to become a leader in developing covalent small molecules for metabolic diseases.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.